Coya Therapeutics (COYA)
Develops Treg-focused therapies for neurodegenerative and immune-mediated diseases.
Something off on this page? Send us feedback.
Develops proprietary therapies intended to enhance regulatory T-cell function across neurodegenerative, inflammatory, autoimmune, and metabolic disease programs. Its development model includes licensed regional commercialization rights for COYA 302.
Develops proprietary therapies intended to enhance regulatory T-cell function, with programs spanning neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet need. COYA 302 is its named lead program, licensed to Dr. Reddy’s Laboratories for ALS commercialization across the United States, Canada, the European Union, and the United Kingdom.
Operates as a clinical-stage development organization rather than a commercial-product company. Development and regulatory progress, together with execution under the COYA 302 licensing arrangement, shape the business. It initially targets disorders with high unmet need across its current clinical programs.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 5, 2026 | Roth Capital | Target | Target: — | Target: $12 |
| Nov 5, 2025 | Lake Street | Target | Target: — | Target: $17 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $43.18B · Total debt $0 · Total assets $47.31B · Shareholders' equity $43.28B
- Revenue
- $243.7K
- Operating income
- −$7.0M
- Net income
- −$6.6M
No dividends on record.
| Institutions | 33.22% | 7.79M shares | |
|---|---|---|---|
| 57 holders · as of Jun 30, 2026 | |||
| Insiders | 4.93% | 1.16M shares | |
| 5 holders · as of Jan 28, 2026 | |||
| Strategic holders | 9.69% | 2.27M shares | |
| 1 holder · as of Mar 12, 2026 | |||
| Other | 52.16% | 12.23M shares | |
| remainder | |||
23.46M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Dme Capital Management, LPInstitution | 9.96% | 2.34M | as of Jun 30, 2026 |
Dr. Reddy's Laboratories, Inc.Strategic | 9.69% | 2.27M | filed Mar 12, 2026 |
Orin HirschmanInsider | 4.72% | 1.11M | filed Jan 28, 2026 |
Vanguard Capital Management LLCInstitution | 3.59% | 842,220 | as of Jun 30, 2026 |
Alyeska Investment Group, L.P.Institution | 3.41% | 800,000 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Nektar Therapeutics
Pegylated IL-2 development for autoimmune diseases
- Xencor
IL-2 Fc-fusion development for autoimmune diseases
- Amgen
IL-2 mutein development for GVHD and autoimmune diseases
- Merck
IL-2 mutein development for autoimmune diseases
- Moderna
mRNA-encoded IL-2 development for autoimmune diseases
- Kyverna Therapeutics
Autologous and allogeneic cell therapies for autoimmune diseases
- Capricor Therapeutics
Cardiosphere-derived exosome development
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Coya Therapeutics | $5.17 | +4.44% | $116.1M | — | — | 14.5 | +35.6% |
| Nektar Therapeutics | $66.47 | −0.55% | $1.92B | — | — | 35.1 | −9.3% |
| Xencor | $25.35 | +1.28% | $1.86B | — | — | 17.7 | +17.5% |
| Amgen | $401.86 | +2.21% | $212.19B | 24.4 | 17.1 | 5.6 | +9.7% |
| Merck | $151.31 | +1.21% | $369.24B | 119.6 | 17.5 | 5.6 | +5.1% |
| Moderna | $180.41 | +4.32% | $68.62B | — | — | 30.8 | +2.1% |
| Kyverna Therapeutics | $7.27 | +2.11% | $432.9M | — | — | — | — |
| Capricor Therapeutics | $9.25 | +3.93% | $511.8M | — | — | — | — |
| Median | 72.0 | 17.3 | 17.7 | +5.1% |